Synthorx
Synthetic DNA with expanded genetic alphabet encoding modified IL-2 cytokine (THOR-707) for cancer immunotherapy
- Sector
- Biotech
- Headquarters
- LA JOLLA, CA
- Founded
- 2014
- Latest Form D
- $26.5M, Apr 2018
- Total capital
- $34.7M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $34.7M
- 3 Form D · last Apr 2018
- 102 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 11
- 29 pending · first 2020
- Rank in peer group#156 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$26.5M
- Private capital raisedForm D · SEC · 2nd filing$5M
- Private capital raisedForm D · SEC · 1st filing$3.1M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#156 · top 11%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Andrew LevinDirectorNamed in SEC Form D filings
- Court TurnerExecutive Officer, DirectorNamed in SEC Form D filings
- Douglas DownsExecutive OfficerNamed in SEC Form D filings
- Floyd RomesbergDirectorNamed in SEC Form D filings
- Jay LichterDirectorNamed in SEC Form D filings
- Laura ShawverExecutive Officer, DirectorNamed in SEC Form D filings
Show all 8 people
- Peter ThompsonDirectorNamed in SEC Form D filings
- Tighe ReardonExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 11 granted of 40- PendingImmuno Oncology Combination Therapy With IL-2 Conjugates And Anti-egfr AntibodiesUSPTOApplication 19305326
- GrantedIL-2 Conjugates and Methods of Use ThereofUSPTOUS 12,521,437
- GrantedInterleukin 10 Conjugates And Uses ThereofUSPTOUS 12,491,254
Show all 40 patent records
- Immuno Oncology Combination Therapy With IL-2 Conjugates And Anti-egfr AntibodiesApr 30, 2026 · Application 19305326Pending
- IL-2 Conjugates and Methods of Use ThereofJan 13, 2026 · US 12,521,437Granted
- Interleukin 10 Conjugates And Uses ThereofDec 9, 2025 · US 12,491,254Granted
- Cytokine Conjugates For The Treatment Of Proliferative And Infectious DiseasesOct 23, 2025 · Application 19025471Pending
- Cytokine Conjugates For The Treatment Of Autoimmune DiseasesOct 23, 2025 · Application 19257936Pending
- Cytokine Conjugates For The Treatment Of Autoimmune DiseasesAug 5, 2025 · US 12,377,131Granted
- Novel IL-15 Conjugates And Uses ThereofJul 1, 2025 · US 12,344,648Granted
- Cytokine Conjugates For The Treatment Of Proliferative And Infectious DiseasesJun 3, 2025 · US 12,318,431Granted
- IL-2 Conjugates and Methods of Use to Treat Autoimmune DiseasesMay 15, 2025 · Application 18886814Pending
- Incorporation Of Unnatural Nucleotides And Methods ThereofMar 13, 2025 · Application 18955271Pending
- Methods For Selecting Subjects And Treating Cancer With IL-2 TherapyMar 6, 2025 · Application 18727910Pending
- IL-2 Conjugates And Methods Of Use To Treat Autoimmune DiseasesFeb 25, 2025 · US 12,234,271Granted
- IL-15 Conjugates and Uses ThereofNov 21, 2024 · Application 18424573Pending
- IL-15 Conjugates and Uses ThereofAug 29, 2024 · Application 18415445Pending
- Head And Neck Cancer Combination Therapy Comprising An IL-2 Conjugate And CetuximabJul 11, 2024 · Application 18524157Pending
- IL-15 Conjugates and Uses ThereofMar 5, 2024 · US 11,919,934Granted
- Immuno Oncology Combination Therapy With IL-2 Conjugates And PembrolizumabSep 7, 2023 · Application 18296710Pending
- Cytokine Conjugates For The Treatment Of Proliferative And Infectious DiseasesJul 18, 2023 · US 11,701,407Granted
- Cytokine Conjugates For The Treatment Of Autoimmune DiseasesApr 11, 2023 · US 11,622,993Granted
- Interleukin 10 Conjugates and Uses ThereofSep 1, 2022 · Application 17735564Pending
- Immuno Oncology Combination Therapy With IL-2 Conjugates And Anti-egfr AntibodiesJan 20, 2022 · Application 17357615Pending
- IL-2 Conjugates And Methods Of Use ThereofAug 3, 2021 · US 11,077,195Granted
- Immuno Oncology Combination Therapies With IL-2 ConjugatesFeb 18, 2021 · Application 16993967Pending
- IL-2 Conjugates And Methods Of Use ThereofAug 6, 2020 · Application 16783095Pending
- Cytokine Conjugates For The Treatment Of Proliferative And Infectious DiseasesJun 11, 2020 · Application 16634479Pending
- Cytokine Conjugates For The Treatment Of Proliferative And Infectious DiseasesApr 7, 2020 · US 10,610,571Granted
- Incorporation Of Unnatural Nucleotides And Methods ThereofJan 23, 2020 · Application 16577347Pending
- Incorporation Of Unnatural Nucleotides And Methods ThereofDec 28, 2017 · Application 15543217Pending
- Lung Cancer Combination Therapy With IL-2 Conjugates And PembrolizumabApplication 63276954Pending
- Skin Cancer Combination Therapy With IL-2 Conjugates And CemiplimabApplication 63276955Pending
- Classic Hodgkin Lymphoma Combination Therapy With IL-2 Conjugates And PembrolizumabApplication 63291654Pending
- Cancer Combination Therapy with IL-2 Conjugates and CetuximabApplication 63293139Pending
- Methods For Selecting Subjects And Treating Cancer With IL-2 TherapyApplication 63299113Pending
- Skin Cancer Combination Therapy With IL-2 Conjugates And CemiplimabApplication PCTUS2022016216Pending
- Head And Neck Cancer Combination Therapy Comprising An IL-2 Conjugate And A PD-1 AntagonistApplication PCTUS2022031968Pending
- Cancer Therapy With IL-2 Conjugates And Chimeric Antigen Receptor TherapiesApplication PCTUS2023085227Pending
- Head And Neck Cancer Combination Therapy Comprising An IL-2 Conjugate And CetuximabApplication PCTUS2022031974Pending
- Classic Hodgkin Lymphoma Combination Therapy With IL-2 Conjugates And An ANTI-PD-1 Antibody Or Antigen-binding Fragment ThereofApplication PCTUS2022081999Pending
- Cancer Therapy With IL-2 Conjugates And Chimeric Antigen Receptor TherapiesApplication PCTUS2022082151Pending
- Head And Neck Cancer Combination Therapy Comprising An IL-2 ConjugateApplication 63214634Pending
Related companies, and why
- Bugworks Research, Inc.Similar federal contract value in Biotech · null in contracts
- Scholar RockSimilar federal contract value in Biotech · null in contracts
- SeaStar Medical, Inc.Similar federal contract value in Biotech · null in contracts
- Contineum TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Pulmatrix Operating Company, Inc.Similar federal contract value in Biotech · null in contracts
- Tarsa Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .